Key Findings
Prior to the BIO International Convention 2026, Pierre-Alain Ruffieux, CEO of Cytiva, strongly asserted that standardization and automation of manufacturing processes are imperative for expanding global patient access to cell and gene therapies (CGT). The goal is to enhance the cost-effectiveness and reproducibility of CGT products, enabling their broader adoption.
Technical / Clinical Details
- Importance of Standardization: Standardization in CGT manufacturing is crucial for reducing process variability and ensuring consistent product quality. Standardized protocols and workflows facilitate technology transfer between different manufacturing sites and streamline regulatory approval processes.
- Efficiency through Automation: The often manual and complex CGT manufacturing process can be dramatically streamlined through automation. Automated systems reduce the risk of human error, increase throughput, and lower manufacturing costs. This enhances the price competitiveness of CGT products.
- Platform-Based Modular Manufacturing: Ruffieux highlighted the advantages of a platform-based modular manufacturing approach. This approach, by combining standardized components and process modules, enables predictable scale-up (increased production volume) and scale-out (expansion of manufacturing facilities). This ensures a smooth transition from development-stage products to commercial production.
- Building Regional Manufacturing Networks: The establishment of regional manufacturing networks was identified as important for strengthening supply chain resilience and ensuring global patient access. Regional hubs allow for manufacturing closer to patients, simplifying logistics, and shortening lead times.
- Digitalization and Data Utilization: Digitalization of manufacturing processes and the utilization of data enable real-time monitoring, predictive analytics, and process optimization, further improving quality control and efficiency.
Background & Context
Cell and gene therapies offer expanding treatment options for a wide range of diseases, but their high costs, complex manufacturing processes, and limited manufacturing capacity remain significant barriers to global patient access. Leading technology providers like Cytiva are actively working to develop solutions to overcome these challenges and enable CGT to become a mainstream therapy.
Strategic Significance & Outlook
The implementation of standardization, automation, and modular platforms in CGT manufacturing will significantly contribute to reducing manufacturing costs, improving efficiency, and strengthening global supply capacity. This will enable more patients to benefit from these innovative therapies, and sustainable growth of the CGT market is expected. Cytiva’s recommendations will serve as a roadmap for the entire industry to collaboratively shape the future of CGT.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments